Vor Biopharma (VOR) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$121.63
- EPS estimate
- −$3.45
- EPS surprise
- −3422.95%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 13, 2025
Vor Biopharma's most recent report in the table covers Q3 2025 and came out on November 13, 2025. It posted a loss of $121.63 per share, against an expected loss of $3.45. A year earlier, in Q3 2024, the loss was $8.00 per share. The table gives no revenue figures or estimates for any quarter, so revenue cannot be compared.
Every quarter in the table was a loss. From Q1 2021 to Q1 2025, losses ran between $5.20 and $13.40 per share, and they generally narrowed over time. The full-year loss was $43.20 per share in 2021, $35.20 in 2023 and $34.00 in 2024; 2022 has no Q4 row. The last two rows break sharply from that range: a loss of $251.22 per share in Q2 2025 and $121.63 in Q3 2025. The data does not say why, and these figures are hard to compare with earlier quarters. Over the 18 quarters shown, Vor beat the EPS estimate 7 times.
Q4 results have come out between March 14 and March 20 in past years. However, the table has no row for Q4 2025 or any 2026 quarter, so it gives no basis for dating the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 13, 2025 | −$3.45 | −$121.63 | −3422.95% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$8.77 | −$251.22 | −2765.58% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$5.26 | −$5.20 | +1.09% | $0.00 | SEC |
| Q4 2024 | Mar 20, 2025 | −$5.71 | −$8.80 | −54.00% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$8.04 | −$8.00 | +0.55% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$8.36 | −$8.20 | +1.86% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$7.56 | −$9.00 | −19.12% | $0.00 | SEC |
| Q4 2023 | Mar 20, 2024 | −$10.06 | −$7.80 | +22.45% | $0.00 | SEC |
| Q3 2023 | Nov 7, 2023 | −$9.36 | −$9.80 | −4.75% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$8.43 | −$9.00 | −6.80% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$7.48 | −$8.60 | −15.05% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$11.89 | −$12.60 | −5.95% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$12.92 | −$11.60 | +10.22% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$10.22 | −$12.20 | −19.40% | $0.00 | — |
| Q4 2021 | Mar 14, 2022 | −$11.20 | −$9.80 | +12.48% | $0.00 | — |
| Q3 2021 | Nov 10, 2021 | −$12.25 | −$10.00 | +18.37% | $0.00 | — |
| Q2 2021 | Aug 9, 2021 | −$9.90 | −$10.00 | −1.01% | $0.00 | — |
| Q1 2021 | May 6, 2021 | −$12.75 | −$13.40 | −5.10% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Vor Biopharma (VOR) last report earnings?
Vor Biopharma last reported on Nov 13, 2025, covering fiscal Q3 2025.
Did VOR beat earnings estimates?
No. Vor Biopharma reported EPS of −$121.63 for Q3 2025 against a −$3.45 estimate — a 3422.95% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.